Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1Suspended 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Neoplasm Metastasis 4Pancreatic Neoplasms 2Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1HTLV-I Infections 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Adenocarcinoma of Lung 1

Interventions

iadademstat 1decitabine and cedazuridine drug combination 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Polycythemia Vera × Biopsy × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡